CO2 STRESS: CO2 as a Stress Agent for Perfusion Imaging

Sponsor

Ottawa Heart Institute Research Corporation (Other)

Overall Status

Terminated

CT.gov ID

NCT02043535

Collaborator

(none)

Enrollment

Location

Arm

79.1

Actual Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Myocardial perfusion imaging (MPI) is a nuclear scan using a radioisotope to see blood flow to the muscles of the heart when the heart is at rest and when it is under stress. The stress test in MPI can be done using medications, such as persantine, that dilate coronary arteries and increase blood flow. Similarly, elevated carbon dioxide (CO2) levels in the blood, or hypercapnia, also dilates arteries and increases blood flow. Thornhill Research Inc. has developed the RA-MR™ sequential gas delivery system used to control CO2 levels in the blood. The RA-MR™ can deliver precise amounts of CO2 through a mouthpiece for inhalation to increase CO2 levels in the blood and thereby increasing blood flow like during stress.

The objective of this study is to compare the differences in blood flow through the arteries of the heart during stress with hypercapnia and adenosine MPI. The imaging will be done using positron emission tomography (PET) with the radioisotope, or tracer, called Rubidium (Rb-82). The Rb-82 is given through a pump, or elution system.

The investigators hypothesize that hypercapnia will induce a stress-to-rest increase in myocardial blood flow by a factor of 2 or more in myocardial regions supplied by non-stenotic arteries in normal volunteers and participants with coronary artery disease.

Condition or Disease	Intervention/Treatment	Phase
Coronary Artery Disease	Device: Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System. Device: Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Effects of Controlled Hypercapnic Stimulation on Myocardial Blood Flow Measured With Positron Emission Tomography

Actual Study Start Date :

Mar 12, 2014

Actual Primary Completion Date :

Oct 15, 2020

Actual Study Completion Date :

Oct 15, 2020

Arms and Interventions

Arm	Intervention/Treatment
Other: Myocardial blood flow quantification The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels. Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging. Persantine stress myocardial PET perfusion imaging: as a standard for comparison.	Device: Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System. All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent. Myocardial perfusion stress testing Other Names: the RA-MR™ System Device: Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI. Other Names: Ruby-Fill™

Arm

Intervention/Treatment

Other: Myocardial blood flow quantification

The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels. Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging. Persantine stress myocardial PET perfusion imaging: as a standard for comparison.

Device: Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.

All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent. Myocardial perfusion stress testing

Other Names:

the RA-MR™ System

Device: Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system

All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.

Other Names:

Ruby-Fill™

Outcome Measures

Primary Outcome Measures

Myocardial blood flow differences [Difference between baseline rest scan blood flow and hypercapnia stress scan myocardial blood flow at 50 mmHg, 55 mmHg, 60 mmHg levels from baseline. Imaging and intervention analysis will be complete in 4 years.]
The myocardial blood flow (MBF) will be quantified with each Rb-82 PET scan done. Polar-maps representing MBF are generated for each rest and stress state using in-house FlowQuant©software. The rest scan will be the baseline. The myocardial blood flow in the four stress scans using hypercapnia as a stress agent will be compared to the rest baseline myocardial blood flow and the adenosine stress scan myocardial blood flow.

Secondary Outcome Measures

Absolute myocardial blood flow differences between end-tidal CO2 scans [Difference between baseline and 60 mmHg PetCO2. Imaging and intervention analysis will be complete in 4 years.]
The effect of increasing doses of pulmonary end-tidal carbon dioxide tension (PetCO2) will be measured and quantification of absolute myocardial blood flow using Rb-82 PET will be calculated. Polar-maps representing MBF are generated for each stress state using in-house FlowQuant©software. Five levels will be measured.
Difference bewteen absolute myocardial blood flow with hypercapnia and with adenosine stress. [Quantification and comparison of the differences in myocardial blood flow with adenosine stress and increasing levels of CO2 as a stress agent. Imaging and intervention analysis will be complete in 4 years.]
The effects of hypercapnia and adenosine on absolute myocardial blood flow using Rb-82 PET will be compared. Polar-maps representing MBF are generated for each stress state using in-house FlowQuant©software.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

For all participants

Age ≥ 18 years old
BMI ≤ 40 kg/m2
Able and willing to comply with the study procedures
Written informed consent
Participants with documented coronary artery disease
Stable coronary artery disease on a stable medication regime.
Healthy volunteers without known heart disease
Low risk of coronary artery disease (CAD)

Exclusion Criteria:

History or risk of severe bradycardia (heart rate < 50 beats per minute) not related to chronotropic drugs
Known second- or third-degree Atrio-ventricular block without pacemaker
Atrial flutter or atrial fibrillation
Dyspnea (NYHA III/IV), wheezing asthma or Chronic Obstructive Pulmonary Disease (COPD)
Coronary artery bypass graft (CABG) surgery within 60 days prior to screening or at any time after consent
Percutaneous coronary intervention (PCI) within 30 days prior to screening or at any time following consent
Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent
Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
Known hypersensitivity to adenosine
Breastfeeding or pregnancy
Claustrophobia or inability to lie still in a supine position
Unwillingness or inability to provide informed consent